Nexgel Inc

Nexgel Inc(NXGL)股票分析

$3.720

-0.359 (-9.65%)收盤時

Loading chart…
最高
3.800
開盤
3.800
成交量加權均價
3.71
成交量
13.83K
市值
13.55M
最低
3.600
成交金額
51.27K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.61

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

AI 分析 of Nexgel Inc (NXGL)

賣出

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

估值指標

Nexgel Inc(NXGL)目前預期本益比為 1.38,5 年平均預期本益比為 -12.03。

預期本益比

合理
5 年均值 P/E
-12.03
目前P/E
1.38
高估
8.24
低估
-32.31

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.87
目前EV/EBITDA
-0.61
高估
104.38
低估
-62.63

預期股價營收比

低估
5 年均值 P/S
2.06
目前P/S
0.08
高估
3.55
低估
0.56

Alphio AI 對 NXGL 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NXGL

$6.00

情境價格

基

基準

基準 · 50%NXGL

$5.53

情境價格

悲

悲觀

悲觀 · 25%NXGL

$5.37

情境價格

事件時間軸

2026-10-09 (ET)

20:00:00

Nexgel Inc Trading Halted, News Pending

2026-08-20 (ET)

16:30:00

Company Establishes Special Committee for Strategic Review

16:30:00

NexGel Appoints Brian Kieser as Interim CEO

13:00:00

Selling Stockholders Plan to Sell 15.25M Shares of Common Stock

2026-05-19 (ET)

09:20:00

NexGel Reports Clinical Study Data Showing 37.2% Reduction in Hair Density

資訊

NXGL 常見問題 —— 由 Alphio AI 解答

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易